pain conditions
Metri Bio raises US$5m for endo therapeutics
Boston biotech Metri Bio has raised US$5m in an oversubscribed pre-seed round to develop endometrial therapies.
The company emerged from stealth with the funding announcement.
The funding will accelerate development of Metri Bio’s discovery platform and therapeutic programmes for endometriosis.
The company will expand its team and research and development operations as it moves toward preclinical studies and future trials.
Metri Bio was co-founded by Berna Sozen, assistant professor at Yale School of Medicine, Ashley Abel, chief executive, and Kathy Potts, chief operating officer.
The company’s technology is based on research from the Sozen Lab at Yale.
It has developed 3D modelling capable of reproducing diseases of the endometrium (the uterus lining), including endometriosis, to study biological mechanisms previously out of reach, the company says.
Abel said: “Metri Bio is grounded in the belief that meaningful innovation in women’s health demands a deep understanding of the biology driving disease.
“Endometriosis affects one in ten women, yet treatments still rely on hormone suppression and repeat surgeries that rarely deliver lasting relief and often cause intolerable side effects.”
The funding round was led by Pillar VC, with participation from Pace Ventures, Slocum Management, Navec Investments and angel investors.
Thomas de Vlaam, partner at Pillar VC and chairman of Metri Bio, said: “It is absurd that a disease paradigm of this magnitude has no good treatment options.
“I’m confident that Metri Bio will play a pivotal role in helping the nearly 200 million women suffering from endometriosis receive the care they deserve.”
Sozen is an internationally recognised researcher in human organoid and developmental modelling technologies.
Potts has a background in translational research and early programme development in women’s health and haematology.
Vipoglanstat has reached the halfway point for patient recruitment in a phase 2 endometriosis trial.
Gesynta Pharma said 50 per cent of the target of 190 patients have been randomised in the NOVA trial.
The study is evaluating vipoglanstat, described by the company as a novel, non-hormonal, non-opioid drug candidate for the treatment of endometriosis.
Endometriosis is a chronic inflammatory condition where tissue similar to the lining of the womb grows outside the uterus, often causing severe pain and, in some cases, infertility.
The condition affects more than 10 per cent of women of reproductive age.
Top-line results from the study are expected in 2027.
The NOVA trial is a randomised, double-blind, placebo-controlled phase 2 proof-of-concept study evaluating vipoglanstat in women with endometriosis across Europe.
This means patients are assigned to treatment groups by chance, neither participants nor researchers know who receives the drug or placebo during the study, and the results are intended to show whether the treatment has enough evidence to move into later testing.
The trial is assessing the efficacy and safety of two dose levels of vipoglanstat and will provide information for the design of a subsequent phase 3 programme.
Eva Johnsson, chief medical officer and vice president of clinical development at Gesynta Pharma, said:
“Reaching the halfway point in patient recruitment marks a major milestone for our Phase 2 clinical trial in endometriosis. Achieved well ahead of schedule, the rapid progress reflects strong participation from clinical sites and great interest among eligible participants. This momentum highlights the urgent need for better treatments.
“We are now eager to complete enrolment and proceed to the next phase of evaluation.”
Patric Stenberg, chief executive of Gesynta Pharma, said:
“The NOVA trial is a significant advancement in a field with few ongoing clinical trials, and a key step toward establishing a strong foundation for a future Phase 3 programme for vipoglanstat.
“Given the immense medical need, our focus remains on delivering a treatment that is highly effective, safe, and well-tolerated.”
Vipoglanstat is an orally active drug candidate designed to reduce pain and inflammation by targeting mPGES-1, an enzyme that produces prostaglandin E2, a substance linked to inflammation in endometriotic lesions.
A preclinical proof-of-concept study in an advanced endometriosis model found that vipoglanstat significantly reduced pain-related behaviours and endometriotic lesion burden.
Gesynta said previous clinical studies have supported the drug candidate’s safety, tolerability and pharmacodynamic effects in humans. Pharmacodynamic effects refer to how a drug acts in the body.
NOVA stands for the Non-hormonal Option, a Vipoglanstat Assessment trial.
Endometriosis commonly presents with severe period pain, known as dysmenorrhoea, pain between periods, pain during sexual intercourse, gastrointestinal symptoms and infertility.
Current management is typically limited to painkillers, hormonal therapies and surgery.
Despite its prevalence, Gesynta said endometriosis remains a critically underserved area of women’s health.
The company said the disease is significantly underdiagnosed and undertreated, with few new treatment options available to patients.
Approximately 190 patients aged 18 to 45 will receive vipoglanstat or placebo over four menstrual cycles.
The primary objective is to evaluate the effect of vipoglanstat on endometriosis-related pain during non-menstrual days.
Secondary objectives include assessing the effect on menstrual pain, known as dysmenorrhoea, pain during sexual intercourse, known as dyspareunia, use of opioid rescue medication and quality-of-life measures.
Changes in endometriotic lesions, areas of tissue linked to the condition, will also be explored using MRI scans.
Gesynta Pharma said its research on targeting mPGES-1 began at Karolinska Institutet in Sweden.
The company said a second drug candidate, GS-073, is ready to enter clinical phase 1 for the treatment of chronic inflammatory pain.
Gesynta Pharma’s shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture and other specialist investors.
A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Supermarket loyalty card data suggests more than a quarter of women buying menstrual products also buy pain relief at the same time.
The findings also suggest women in lower-income areas are significantly less likely to do so, pointing to disparities in access to over-the-counter pain relief across England.
The study was led by Dr Victoria Sivill of the University of Bristol and colleagues.
The authors said: “The study highlights the need for greater awareness and policy interventions to address the high prevalence of menstrual pain as well as socioeconomic dimensions of menstrual pain.
“Public health initiatives should incorporate menstrual pain relief as part of broader efforts to improve health equity.”
Researchers analysed anonymised loyalty card data from a major UK health and beauty retailer, covering 211m transactions by 3.4m people between 2006 and 2015.
The study examined how often shoppers bought menstrual products and pain relief in the same transaction, and compared this with a customer’s usual rate of buying pain relief.
It found that 26.7 per cent of customers who bought menstrual products also bought pain relief at the same time.
These customers were nearly four times more likely to buy pain relief when buying menstrual products than on other shopping trips.
As a check on the approach, researchers found the most common interval between consecutive menstrual product purchases was exactly 28 days, consistent with the average menstrual cycle.
Menstrual pain is common and can affect daily activities, including school and work attendance.
Regional income was the strongest predictor of menstrual pain purchases.
Customers in the lowest-income areas were 32 per cent less likely to buy pain relief at the same time as menstrual products than those in the highest-income areas.
The authors said lower rates of pain relief purchases in deprived areas are likely to reflect an inability to afford over-the-counter medication rather than lower rates of menstrual pain itself.
Co-author Dr James Goulding said: “It is wonderful that smart data research in the UK is able to bring issues which may have once been overlooked in scientific settings, such as the sheer scale and impact of menstrual pain, to light. This is well overdue.
Co-author Dr Anya Skatova said: “Like many women, I was aware of how common menstrual pain is, but the scale of painkiller purchases alongside menstrual products was still striking.
“Using shopping data, we can see just how widespread the need for pain relief really is. This kind of evidence helps make menstrual pain visible at a population level and provides a strong foundation for systemic change in how it is recognised, treated, and prioritised in public health.”
Insight4 weeks agoBritish women among angriest in Europe, health survey reveals
Menopause3 weeks agoApple Health adds menopause and perimenopause tracking
News3 weeks agoFemtech World Awards 2026: Winners revealed
News4 weeks agoElation Health acquires EHR startup Aster
News4 weeks agoMenopause workplace toolkit launched to help UK employers support staff
Entrepreneur3 weeks agoWomen’s Health Week Europe 2026 opens pitch applications for mainstage showcase at The Emirates Stadium
Menopause3 weeks agoOral GLP-1 shows significant weight loss in all menopause stages – study
News1 week agoOvum secures US$4m in seed funding